Inyigo y'ubuvuzi ya ATG-022 yageze ku musaruro mwiza: CR yageze ku murwayi wa kanseri y'igifu ugeze mu za bukuru

Vuba aha, inyigo ya Antengene's Phase I/II CLINCH kuri ATG-022 (CLDN18.2 antibody-drug conjugate), umurwayi ugeze mu zabukuru ufite kanseri yo mu gifu yateye imbere, wakomeje kuvura indwara zitandukanye, ubudahangarwa bw'umubiri ndetse n'ubuvuzi bugamije imiti nubwo habayeho kanseri nyinshi, yabonye igisubizo cyuzuye (CR) nyuma yo kuvurwa na ATG-022. PET/CT yemeje ko nta kibyimba cy'umurwayi kibayeho muri Gicurasi 2025.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Indangamuntu ya WeChat: 17801183037

Email：myimmnet@163.com

ATG-022 ni CLDN18.2 ADC yavumbuwe kandi ikorwa na Antengene. Mu nama ya ASCO GI 2025 mu ntangiriro z'uyu mwaka, Antengene yagaragaje amakuru avuguruye y’ubuvuzi kuri ATG-022. Ku barwayi bafite CLDN18.2 iri hagati y’ibyiciro biri hagati (IHC 2+ ≥ 20%), igipimo cy’ubutabazi bw’ibanze (ORR) cyari 42.9%, naho igipimo cyo kurwanya indwara (DCR) cyari 95.2%. Mu barwayi bafite CLDN18.2 iri hasi (IHC 2+ < 20%), ORR yari 30.0%, naho DCR yari 50.0%. Aya makuru agaragaza ko ATG-022 itanga umusaruro mwiza mu buvuzi n’umutekano mwiza mu byiciro bitandukanye by’ubutabazi bwa CLDN18.2, harimo ubutabazi buri hejuru, buke, ndetse n’ubutabazi buri hasi cyane. Imikorere yayo yo kurwanya kanseri mu buryo bwagutse igaragaza ko ATG-022 ishobora gutanga inyungu ku barwayi benshi ugereranije n'ubundi buryo bwo kuvura bwibanda kuri CLDN18.2. Ubu, inyigo yo kwagura dose ya ATG-022 mu cyiciro cya kabiri irakomeje mu Bushinwa na Ositaraliya.

Uku kuntu uyu murwayi wa kanseri y'igifu yageze kuri CR ni ikintu gishimishije cyane, bigaragaza ubushobozi bwo kuvura bwa ATG-022 nk'uburyo bushya bwo kuvura bwa ADC. Icy'ingenzi ni uko iyi atari yo CR yonyine yagaragaye mu bushakashatsi buri gukorwa. Kugeza ubu, hamaze kugaragara abantu batatu barwaye CR, barimo abarwayi bo mu Bushinwa na Ositaraliya. Antengene yiteguye gutanga amakuru mashya yavuye mu bushakashatsi bwa ATG-022 mu nama ya ESMO izaba mu Ukwakira 2025.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Indangamuntu ya WeChat: 17801183037

Email：myimmnet@163.com